MedTrace Logo

Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC

NCT00510107 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2007-08-01

No results posted yet for this study

Summary

To evaluate the efficacy and safety of weekly administered combination of docetaxel/cisplatin and docetaxel/oxaliplatin in chemotherapy-naïve patients with advanced gastric cancer. The primary endpoint will be the response rate.

Conditions

  • Stomach Neoplasm
  • Stage IV
  • Recurrent

Interventions

DRUG

oxaliplatin

oxaliplatin 120 mg/m2 will be given on day 1.

DRUG

Cisplatin

Cisplatin 60 mg/m2 will be given on day 1.

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Gachon University Gil Medical Center

    lead OTHER

Principal Investigators

  • Se Hoon Park, MD · Gachon University Gil Medical Center, Incheon, Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Completion
2009-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00510107 on ClinicalTrials.gov